Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Large Growth in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 16,171 shares, an increase of 298.4% from the November 30th total of 4,059 shares. Based on an average daily trading volume, of 20,878 shares, the short-interest ratio is presently 0.8 days. Currently, 1.3% of the company’s shares are sold short. Currently, 1.3% of the company’s shares are sold short. Based on an average daily trading volume, of 20,878 shares, the short-interest ratio is presently 0.8 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc grew its position in shares of Global X Genomics & Biotechnology ETF by 20.8% in the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after buying an additional 489 shares during the last quarter. Halbert Hargrove Global Advisors LLC increased its position in Global X Genomics & Biotechnology ETF by 182.4% during the 2nd quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock valued at $115,000 after purchasing an additional 8,839 shares during the period. HighTower Advisors LLC increased its position in Global X Genomics & Biotechnology ETF by 16.7% during the 1st quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock valued at $121,000 after purchasing an additional 2,184 shares during the period. Smartleaf Asset Management LLC raised its holdings in Global X Genomics & Biotechnology ETF by 18.5% during the 1st quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock worth $125,000 after purchasing an additional 2,329 shares during the last quarter. Finally, Oxinas Partners Wealth Management LLC lifted its position in shares of Global X Genomics & Biotechnology ETF by 12.1% in the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after purchasing an additional 1,751 shares during the period. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Down 0.9%

Shares of GNOM stock traded down $0.44 during trading hours on Friday, hitting $47.21. 2,949 shares of the company’s stock traded hands, compared to its average volume of 14,348. The stock’s 50 day simple moving average is $45.02 and its 200 day simple moving average is $39.37. The stock has a market cap of $57.60 million, a PE ratio of -20.18 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a 12 month low of $27.20 and a 12 month high of $48.09.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.